Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Publication Title
Rheumatology (Oxford, England)
Document Type
Article
Publication Date
1-13-2024
Keywords
ACR; MDA; PASI; bimekizumab; disease-modifying antirheumatic drugs; network meta-analysis; psoriatic arthritis; systematic literature review; washington; swedish
Abstract
OBJECTIVES: To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of interleukin-17F in addition to IL-17A, vs other biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for psoriatic arthritis (PsA) using network meta-analysis (NMA).
METHODS: A systematic literature review (most recent update conducted on 01 January 2023) identified randomised controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12-24 for b/tsDMARD-naïve and tumour necrosis factor inhibitor (TNFi) -experienced (exp) patients. Safety at Weeks 12-24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank.
RESULTS: The NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-exp patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th, and 3rd for American College of Rheumatology response (ACR)20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd, and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index [PASI]90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-exp patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events.
CONCLUSION: Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin, and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA.
Clinical Institute
Orthopedics & Sports Medicine
Specialty/Research Institute
Orthopedics
Specialty/Research Institute
Rheumatology
Specialty/Research Institute
Pharmacy
DOI
10.1093/rheumatology/kead705
